We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

BioCryst Shareholders Sue Over Idera Merger Plan

Law360 (March 8, 2018, 3:33 PM EST) -- BioCryst Pharmaceuticals Inc. and its board of directors have undervalued the biotechnology company by agreeing to a “merger of equals” with Idera Pharmaceuticals Inc., a shareholder says in a proposed class action filed this week in Delaware federal court.

BioCryst shareholder Melvyn Klein says in Tuesday’s complaint that the January merger agreement would not fairly compensate the company’s investors in light of BioCryst’s potential treatment for hereditary angioedema and of other “valuable” drugs in development. The merger would also require BioCryst shareholders to adopt a riskier...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.